Cardiff Oncology announces participation in two conferences focusing on PLK1 inhibition and colorectal cancer treatment advancements.
Quiver AI Summary
Cardiff Oncology, Inc. has announced that Dr. Mani Mohindru will participate in two upcoming conferences, the 8th Annual RAS-Targeted Drug Development Summit on September 8 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. The company, which focuses on developing innovative cancer therapies through PLK1 inhibition, highlights its lead asset, onvansertib, currently in a Phase 2 trial for RAS-mutated metastatic colorectal cancer. After the conferences, presentations and webcasts will be accessible on the Cardiff Oncology website. The company aims to address unmet needs in cancer treatment by targeting tumor vulnerabilities and has shown promising results in challenging cancer types.
Potential Positives
- Participating in two notable conferences highlights Cardiff Oncology's commitment to advancing their research and broadening their visibility within the oncology community.
- The focus on RAS-mutant metastatic colorectal cancer positions Cardiff Oncology to address a significant unmet need in a large patient population, which could enhance the company's reputation and market potential.
- The ongoing investigation of onvansertib in various cancers demonstrates the potential for diversified applications of their lead asset, indicating robust pipeline prospects for the company.
- Providing access to presentation materials and live webcasts fosters transparency and engagement with investors and stakeholders, enhancing communication and trust in the company.
Potential Negatives
- Company is still in clinical stages, which may indicate a long path to market and uncertainty regarding future revenue generation.
- Participation in conferences may highlight the company's need for increased visibility and investor interest, suggesting potential difficulties in gaining traction.
FAQ
What is Cardiff Oncology's main focus?
Cardiff Oncology focuses on developing novel therapies targeting PLK1 inhibition for various cancer types.
Who will represent Cardiff Oncology at the upcoming conferences?
Mani Mohindru, Ph.D. will represent Cardiff Oncology at the upcoming conferences.
When is the 8th Annual RAS-Targeted Drug Development Summit?
The summit will be held on Tuesday, September 8 at 9:00 AM ET.
How can I access the conference presentations after they conclude?
Interested parties can access slides in the “Events” section of the Cardiff Oncology website.
What is onvansertib being evaluated for?
Onvansertib is being evaluated as a first-line treatment for RAS-mutated metastatic colorectal cancer.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRDF Insider Trading Activity
$CRDF insiders have traded $CRDF stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CRDF stock by insiders over the last 6 months:
- GARY W PACE has made 2 purchases buying 717,285 shares for an estimated $1,036,599 and 0 sales.
- MANI MOHINDRU (Chief Executive Officer) has made 2 purchases buying 59,067 shares for an estimated $79,890 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CRDF Hedge Fund Activity
We have seen 56 institutional investors add shares of $CRDF stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,008,514 shares (-75.6%) from their portfolio in Q2 2026, for an estimated $3,911,068
- ACORN CAPITAL ADVISORS, LLC removed 1,762,084 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,290,709
- BLAIR WILLIAM & CO/IL removed 1,036,334 shares (-53.2%) from their portfolio in Q2 2026, for an estimated $1,347,234
- STATE STREET CORP removed 855,552 shares (-72.1%) from their portfolio in Q2 2026, for an estimated $1,112,217
- GEODE CAPITAL MANAGEMENT, LLC removed 779,601 shares (-48.7%) from their portfolio in Q2 2026, for an estimated $1,013,481
- JANE STREET GROUP, LLC added 567,795 shares (+1415.8%) to their portfolio in Q2 2026, for an estimated $738,133
- LAURION CAPITAL MANAGEMENT LP added 451,561 shares (+17.1%) to their portfolio in Q2 2026, for an estimated $587,029
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
Details of the company’s participation are as follows:
-
8
th
Annual RAS-Targeted Drug Development Summit
-
Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesday, September 8 at 9:00 AM ET
-
Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesday, September 8 at 9:00 AM ET
-
H.C. Wainwright 28
th
Annual Global Investment Conference
-
Fireside Chat; Monday, September 14 at 10:00 AM ET
-
Fireside Chat; Monday, September 14 at 10:00 AM ET
After the conclusions of these events, interested parties can access slides by visiting the “ Events ” section of the Cardiff Oncology website. In addition, for the H.C. Wainwright conference, interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. That webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Investor
Contact:
Candice Masse
Astr Partners
[email protected]
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]
